The approval makes remibrutinib the first targeted therapy approved for symptomatic dermographism, expanding its indication beyond chronic spontaneous urticaria.

The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...

Serum ferritin threshold of less than or equal to 20ng/mL is suggested for children ages 9 months to 4 years. HealthDay News — In guidelines issued by the American Society of Hematology and published ...

Phase 3b trial shows long-acting injectable therapy outperforms daily oral regimens for patients with detectable HIV-1 and adherence challenges.

Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.

FDA clearance of Motivista introduces a novel prescription digital therapeutic specifically indicated to target experiential negative symptoms in adults with schizophrenia.

Net decreases in prevalence seen across age groups, with largest relative reduction for young adults aged 18 to 29 years.

Combined tobacco and e-cigarette exposure linked to increase in activity-related symptoms, nighttime symptoms, albuterol use.

In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.

Epcoritamab combined with R-CHOP significantly improved progression free survival in patients with newly diagnosed DLBCL across both the primary endpoint and total populations.

Pivotal adult trial data support planned BLA submission for Vaxcyte's investigational 31-valent pneumococcal conjugate vaccine candidate.

The estimated 5-year risk for the renal outcome was 2.4 vs 2.1% for people taking GLP-1 receptor agonists or SGLT-2 inhibitors vs those taking DPP-4 inhibitors. HealthDay News — For adults with type 2 ...